Tempest Therapeutics Inc (NAS:TPST)
$ 1.42 -0.04 (-2.74%) Market Cap: 35.80 Mil Enterprise Value: 24.93 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 36/100

Tempest Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 06:00PM GMT
Release Date Price: $1.39 (-5.44%)
Tom Dubensky
Tempest Therapeutics, Inc. - President

Tempest is a public company. I will be making forward-looking statements today. Please see our SEC filings.

Tempress represents a diversified oncology investment opportunity. We have four programs spanning two drugs in clinic right now. A preclinical program that is late in the preclinical setting that we are optimistic will be in clinic next year and an undisclosed opportunity that is we think not being explored by anyone else in the industry at this point.

The four programs that we have are mechanistically independent and we think represent four unique shots on goal. Each of them standing on their own in terms of an opportunity in significant cancer indications. We are funded through 2024, and through potential value inflection point.

The oncology pipeline is shown here. The first compound TPST-1120 is a novel oral inhibitor of the transcription of the ligand activated transcription factor of PPAR alpha. This drug will be a first-in-class compound if approved. The TPST-1120 has completed a first -- our Phase-1 program

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot